Literature DB >> 17372713

[Urticaria. "From bench to bedside"].

M Magerl1, M Maurer.   

Abstract

A number of recent epidemiologic and experimental studies have enhanced our knowledge of the etiology and pathogenesis of urticaria. In addition, new instruments for diagnosing urticaria variants and for assessing the quality of life in urticaria patients have been developed. Finally, several clinical trials have demonstrated the efficacy of novel treatment approaches for urticaria, while other therapeutic concepts are under development. Here, we provide a brief review of selected findings from these recent reports and a discussion of their relevance for clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372713     DOI: 10.1007/s00105-007-1288-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  37 in total

1.  Immune profiles of patients with chronic idiopathic urticaria.

Authors:  Stefania Piconi; Daria Trabattoni; Enrico Iemoli; Maria Luisa Fusi; Maria Luisa Villa; Francesco Milazzo; Mario Clerici
Journal:  Int Arch Allergy Immunol       Date:  2002-05       Impact factor: 2.749

Review 2.  EAACI/GA2LEN/EDF guideline: management of urticaria.

Authors:  T Zuberbier; C Bindslev-Jensen; W Canonica; C E H Grattan; M W Greaves; B M Henz; A Kapp; M M A Kozel; M Maurer; H F Merk; T Schäfer; D Simon; G A Vena; B Wedi
Journal:  Allergy       Date:  2006-03       Impact factor: 13.146

3.  Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells.

Authors:  S Molet; P Gosset; P Lassalle; W Czarlewski; A B Tonnel
Journal:  Clin Exp Allergy       Date:  1997-10       Impact factor: 5.018

4.  Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies.

Authors:  R A Sabroe; P T Seed; D M Francis; R M Barr; A K Black; M W Greaves
Journal:  J Am Acad Dermatol       Date:  1999-03       Impact factor: 11.527

5.  Cellular adhesion molecules in chronic urticaria: modulation of serum levels occurs during levocetirizine treatment.

Authors:  M Caproni; W Volpi; B Giomi; D Torchia; E Del Bianco; P Fabbri
Journal:  Br J Dermatol       Date:  2006-12       Impact factor: 9.302

6.  Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines.

Authors:  C Traidl-Hoffmann; I Münster; J Ring; H Behrendt
Journal:  Int Arch Allergy Immunol       Date:  2006-06-02       Impact factor: 2.749

Review 7.  [Relevance of food allergies and intolerance reactions as causes of urticaria].

Authors:  M Maurer; A Hanau; M Metz; M Magerl; P Staubach
Journal:  Hautarzt       Date:  2003-01-29       Impact factor: 0.751

Review 8.  Immunomodulating effect of autohaemotherapy (a literature review).

Authors:  N N Klemparskaya; G A Shalnova; A M Ulanova; T D Kuzmina; A D Chuhrov
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1986

9.  Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study.

Authors:  E Nettis; M C Colanardi; M T Paradiso; A Ferrannini
Journal:  Clin Exp Allergy       Date:  2004-09       Impact factor: 5.018

10.  Correlation between T-cell and mast cell activity in patients with chronic urticaria.

Authors:  Bernadett Hidvégi; Eszter Nagy; Teréz Szabó; Erzsébet Temesvári; Márta Marschalkó; Sarolta Kárpáti; Attila Horváth; Péter Gergely
Journal:  Int Arch Allergy Immunol       Date:  2003-10       Impact factor: 2.749

View more
  1 in total

1.  [Omalizumab for therapy-resistant chronic urticaria with angioedema].

Authors:  H Korkmaz; S Eigelshoven; B Homey
Journal:  Hautarzt       Date:  2010-10       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.